Deutsche Bank AG London Pre Stabilisation Notice - GlaxoSmithKline Capital (4182M)
16 Septiembre 2019 - 2:31AM
UK Regulatory
TIDMAG99
RNS Number : 4182M
Deutsche Bank AG London
16 September 2019
16-Sep-19
Not for distribution, directly or indirectly, in or into the
United States or any jurisdiction in
which such distribution would be unlawful
GlaxoSmithKline Capital plc
Pre-stabilisation Period Announcement
Deutsche Bank AG, London Branch (contact: DCM on 0207-545-4153)
hereby gives notice, as Stabilisation Coordinator, may that the
Stabilisation Manager(s) named
below may stabilise the offer of the following securities in
accordance with Commission
Delegated Regulation EU 2016 under the Market Abuse Regulation
(EU/596/2014).
The Securities:
Issuer: GlaxoSmithKline Capital plc
Guarantor (if any): GlaxoSmithKline plc
Aggregate nominal amount: TBC
Description: GSK 2y FRN/FXD & 4yr EUR
Issue/reoffer price: TBC
Other offer terms:: TBC
Stabilisation:
Stabilising Manager(s): BNPP, CS, DB, MS
Stabilisation period 16-Sep-19
expected to start on:
Stabilisation period
expected to end no later than: 21-Oct-19
Existence, maximum size and conditions of The Stabilisation Manager(s) may over--allot the
use of over--allotment securities to the extent permitted in
accordance
with applicable law8.
Stabilisation trading TBC
In connection with the offer of the above securities, the
Stabilisation Manager(s) may
over--allot the securities or effect transactions with a view to
supporting the market price of
the securities during the stabilisation period at a level higher
than that which might otherwise
prevail. However, stabilisation may not necessarily occur and
any stabilisation action, if begun,
may cease at any time9. Any stabilisation action or
over--allotment shall be conducted in
accordance with all applicable laws and rules.
This announcement is for information purposes only and does not
constitute an invitation or
offer to underwrite, subscribe for or otherwise acquire or
dispose of any securities of the
Issuer in any jurisdiction.
In addition, if and to the extent that this announcement is
communicated in, or the offer of
the securities to which it relates is made in, any EEA Member
State that has implemented
Directive 2003/71/EC, as amended (together with any applicable
implementing measures in
any Member State, the "Prospectus Directive") before the
publication of a prospectus in
relation to the securities which has been approved by the
competent authority in that
Member State in accordance with the Prospectus Directive (or
which has been approved by a
competent authority in another Member State and notified to the
competent authority in that
Member State in accordance with the Prospectus Directive), this
announcement and the offer
are only addressed to and directed at persons in that Member
State who are qualified
investors within the meaning of the Prospectus Directive (or who
are other persons to whom
the offer may lawfully be addressed) and must not be acted on or
relied on by other persons
in that Member State11.
This announcement is not an offer of securities for sale into
the United States. The securities
have not been, and will not be, registered under the United
States Securities Act of 1933 and
may not be offered or sold in the United States absent
registration or an exemption from
registration. There will be no public offer of securities in the
United States.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
STAEAXNKFAKNEEF
(END) Dow Jones Newswires
September 16, 2019 03:31 ET (07:31 GMT)
Glaxosmsc 5.25% (LSE:AG99)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Glaxosmsc 5.25% (LSE:AG99)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024